NEW YORK, NY — As 2025 comes to a close, Pfizer Inc. reflects on a year marked by strategic execution, scientific progress, and a continued commitment to delivering breakthrough medicines for patients worldwide. Against a rapidly evolving global healthcare landscape, the company strengthened its portfolio, advanced key pipeline assets, and deepened its focus on long-term, innovation-driven growth.
Operational Discipline and Financial Resilience
Throughout 2025, Pfizer demonstrated disciplined operational performance, reaffirming full-year financial guidance and maintaining a strong balance between investment in research and prudent cost management. The company entered the year focused on stabilizing post-pandemic revenue dynamics and exits 2025 with greater clarity, resilience, and confidence heading into 2026.
Pipeline Momentum Across Core Therapeutic Areas
Pfizer made meaningful progress across its priority therapeutic areas, including oncology, vaccines, rare diseases, inflammation, and metabolic disorders. Regulatory milestones, late-stage clinical advancements, and targeted acquisitions during the year reinforced Pfizer’s strategy to focus on high-value, science-led programs with the potential to address significant unmet medical needs.
Accelerating Innovation Through AI and Digital Science
In 2025, Pfizer continued to expand the use of artificial intelligence and advanced digital technologies across discovery, development, and operations. AI-enabled platforms played an increasingly important role in target identification, clinical trial optimization, and data-driven decision-making, strengthening R&D productivity and accelerating timelines from laboratory to patient.
Commitment to Patient-Centric Research
Patient engagement and inclusive clinical research remained central to Pfizer’s mission in 2025. The company advanced efforts to modernize clinical trials, broaden patient participation, and integrate real-world evidence—ensuring that innovation translates into meaningful outcomes for diverse patient populations.
Navigating Challenges with Transparency
Like the broader biopharmaceutical industry, Pfizer faced scientific, regulatory, and operational challenges during the year. The company reiterated its commitment to scientific rigor, patient safety, and transparency, working closely with regulators, investigators, and healthcare partners to responsibly advance innovation.
Executive Commentary
Albert Bourla, Chairman and Chief Executive Officer, Pfizer Inc., said:
“2025 was a year of focus and execution. We strengthened our pipeline, advanced transformative science, and continued integrating technology to power innovation. As we enter 2026, Pfizer is well positioned to deliver meaningful medicines, unlock long-term value, and improve health outcomes for patients around the world.”
Looking Ahead to 2026
As Pfizer steps into the new year, the company’s priorities remain clear:
- Advancing high-impact medicines across core therapeutic areas
- Scaling the use of AI and digital innovation in R&D
- Delivering sustainable growth through disciplined execution
- Expanding access to medicines globally
With more than 175 years of scientific leadership, Pfizer enters 2026 focused on shaping the future of medicine—driven by innovation, powered by technology, and guided by purpose.
By